FaDu Cells
CAD$545.10*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | FaDu is a human cell line derived from a squamous cell carcinoma of the hypopharynx. Established from a tumor in an adult patient, FaDu cells are frequently used in medical research focusing on cancer biology, particularly in studies related to head and neck cancers. These cells exhibit epithelial morphology and are adherent in culture conditions. FaDu is known for its robust growth and is often employed in assays to understand cancer cell proliferation, response to therapeutic agents, and gene expression related to cancer progression and metastasis. In scientific research, FaDu cells have been instrumental in examining the efficacy of radiotherapy and chemotherapy treatments, providing insights into cellular responses to DNA damage and repair mechanisms. The cell line has also been utilized in studies exploring molecular pathways involved in cancer, such as the EGFR signaling pathway, which is often altered in head and neck cancers. The versatility and relevance of FaDu cells make them a valuable model for oncology research, contributing to the development of targeted therapies and understanding cancer cell biology at a molecular level. |
|---|---|
| Organism | Human |
| Tissue | Pharynx |
| Disease | Hypopharyngeal squamous cell carcinoma |
| Synonyms | FaDU, FADU |
Characteristics
| Age | 56 years |
|---|---|
| Gender | Male |
| Ethnicity | Asian |
| Morphology | Epithelial |
| Growth properties | Adherent |
Regulatory Data
| Citation | FaDu (Cytion catalog number 305033) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_1218 |
Biomolecular Data
| Tumorigenic | Yes |
|---|
Handling
| Culture Medium | EMEM (MEM Eagle), w: 2 mM L-Glutamine, w: 2.2 g/L NaHCO3, w: EBSS (Cytion article number 820100a) |
|---|---|
| Supplements | Supplement the medium with 10% FBS and 1% NEAA |
| Dissociation Reagent | Accutase |
| Subculturing | Remove the old medium from the adherent cells and wash them with PBS that lacks calcium and magnesium. For T25 flasks, use 3-5 ml of PBS, and for T75 flasks, use 5-10 ml. Then, cover the cells completely with Accutase, using 1-2 ml for T25 flasks and 2.5 ml for T75 flasks. Let the cells incubate at room temperature for 8-10 minutes to detach them. After incubation, gently mix the cells with 10 ml of medium to resuspend them, then centrifuge at 300xg for 3 minutes. Discard the supernatant, resuspend the cells in fresh medium, and transfer them into new flasks that already contain fresh medium. |
| Fluid renewal | 2 to 3 times per week |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
| Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
Certificate of Analysis (CoA)
| Lot Number | Certificate Type | Date | Catalog Number |
|---|---|---|---|
| 305033-260923 | Certificate of Analysis | 23. May. 2025 | 305033 |
| 305033-260825 | Certificate of Analysis | 22. Oct. 2025 | 305033 |
| 305033-101022 | Certificate of Analysis | 23. May. 2025 | 305033 |